Figure 1 | Scientific Reports

Figure 1

From: A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress

Figure 1

ACE-2020-EGb761 Study Flow Chart. The ACE-2020-EGb761 study was initially designed as a Phase IV, single-center, randomized, open-label, parallel-group clinical trial consisting of the 12-month follow-up of a cohort of participants with MCI (version 1). In January 2022, an extension with an additional 12-month follow-up period was approved.

Back to article page